Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.
Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P; Swiss IBDnet.
Vavricka SR, et al. Among authors: de saussure p.
Inflamm Bowel Dis. 2011 Jul;17(7):1530-9. doi: 10.1002/ibd.21521. Epub 2010 Dec 22.
Inflamm Bowel Dis. 2011.
PMID: 21674709
Clinical Trial.